FreedomWorks Foundation Statement in Response to State of the Union Comments on Drug Prices

WASHINGTON, D.C. — In response to President Trump’s comments on the cost of prescription drug prices, Patrick Hedger, FreedomWorks Foundation’s Director of Policy, commented:

“While we share with the President’s concern with the issues surrounding the rise of prescription drug prices, the focus on prices found in foreign countries is misleading. These prices are achieved through coercive means and stifle innovation. America remains the leading engine for pharmaceutical investment and innovation and this cannot be sacrificed as part of healthcare reform. The President and Congress should focus their efforts on continuing to reduce regulations on pharmaceutical companies and encourage competition in a free American marketplace.”